Physician profile
John Ghassan
NPI 1962992883
$1,875.01
in general payments reported to CMS, 2019-2025
25 companies · $571 in 2025
The $571 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $300 · 2024: $1,004 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $426.04 | 2023-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $170.88 | 2023-2025 | Shingrix, Bexsero, Arexvy |
| Merck Sharp & Dohme LLC | $145.22 | 2024-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $116.82 | 2023-2025 | Spravato, Xarelto |
| Shield Therapeutics INC | $96.43 | 2024 | |
| Novo Nordisk INC | $89.42 | 2023-2025 | Wegovy |
| Xeris Pharmaceuticals, INC. | $86.06 | 2024-2025 | Gvoke Hypopen |
| Cranial Technologies, INC | $83.85 | 2024-2025 | Doc Band |
| Abbvie INC. | $80.35 | 2024-2025 | |
| Dexcom, INC. | $78.10 | 2025 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $62.59 | 2025 | Jornay Pm |
| Exact Sciences Corporation | $48.45 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.64 | 2024 | Xifaxan |
| Sanofi Pasteur INC. | $47.41 | 2023-2025 | |
| Alk-Abello, INC | $46.82 | 2025 | Neffy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $46.25 | 2023-2024 | Contrave, Onzetra Xsail, Nexlizet |
| Lilly USA, LLC | $41.13 | 2023 | Jardiance |
| Kyowa Kirin, INC. | $26.10 | 2025 | |
| Corium, LLC | $25.54 | 2023 | Azstarys |
| Avion Pharmaceuticals | $24.98 | 2023 | Methylphenidate Hydrochloride |
| Dynavax Technologies Corporation | $22.92 | 2024 | Heplisav-B |
| Pfizer INC. | $17.79 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.50 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.46 | 2024 | Airsupra |
| Phathom Pharmaceuticals, INC. | $14.26 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ghassan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.